Metoclopramide Baxter: Uses, Dosage & Side Effects

What Is Metoclopramide Baxter and What Is It Used For?

Metoclopramide Baxter contains the active substance metoclopramide hydrochloride, a substituted benzamide derivative that belongs to the class of dopamine D2 receptor antagonists with additional prokinetic properties. Metoclopramide was first synthesized in 1964 by Dr. Louis Justin-Besançon and Charles Laville at Laboratoires Delagrange in France. It was initially developed as a treatment for nausea and vomiting but was quickly recognized for its dual action as both an antiemetic and a gastrointestinal prokinetic agent. Today, metoclopramide is listed on the WHO Model List of Essential Medicines, highlighting its importance in global healthcare systems.

The mechanism of action of metoclopramide involves multiple pharmacological targets that work in concert to produce its therapeutic effects. As a dopamine D2 receptor antagonist, metoclopramide blocks dopamine receptors in the chemoreceptor trigger zone (CTZ) of the area postrema, located in the floor of the fourth ventricle of the brain. The CTZ is outside the blood-brain barrier and serves as a key relay station for emetic stimuli from the bloodstream. By blocking dopamine-mediated signaling in the CTZ, metoclopramide raises the threshold for emetic stimulation and thereby prevents nausea and vomiting triggered by drugs, metabolic disturbances, and other chemical stimuli.

In addition to its central antiemetic action, metoclopramide exerts significant prokinetic effects on the upper gastrointestinal tract through two complementary mechanisms. First, it blocks dopamine D2 receptors on smooth muscle cells and myenteric neurons in the stomach and proximal small intestine, removing the inhibitory influence of dopamine on gastric motility. Second, it acts as an agonist at serotonin 5-HT4 receptors on enteric neurons, stimulating the release of acetylcholine from the myenteric plexus. The net result is enhanced gastric contractility, accelerated gastric emptying, increased coordination of gastroduodenal contractions (antroduodenal coordination), relaxation of the pyloric sphincter, and increased tone of the lower esophageal sphincter. These prokinetic effects are particularly relevant in conditions such as gastroparesis, where delayed gastric emptying causes symptoms of nausea, bloating, early satiety, and vomiting.

Metoclopramide also has weak antagonist activity at serotonin 5-HT3 receptors, which may contribute to its antiemetic efficacy at higher doses, particularly in the context of chemotherapy-induced nausea and vomiting. However, at the currently recommended doses, this 5-HT3 antagonist activity is considered to play a minor role compared with its D2 antagonism and 5-HT4 agonism.

Metoclopramide Baxter injection (5 mg/ml) is indicated for the following clinical conditions in adults:

• Prevention and treatment of postoperative nausea and vomiting (PONV): Metoclopramide is used perioperatively to reduce the incidence and severity of nausea and vomiting following surgical procedures, particularly those associated with a high emetic risk such as gynecological, ophthalmic, and abdominal surgery.
• Prevention of delayed chemotherapy-induced nausea and vomiting (CINV): As part of multimodal antiemetic regimens, metoclopramide is used to prevent delayed nausea and vomiting occurring more than 24 hours after chemotherapy administration.
• Radiotherapy-induced nausea and vomiting: Metoclopramide helps manage nausea and vomiting associated with radiation therapy, particularly involving the upper abdomen or total body irradiation.
• Symptomatic treatment of gastroparesis: Short-term parenteral administration of metoclopramide is used when oral formulations are not feasible in patients with delayed gastric emptying, particularly in diabetic gastroparesis or post-surgical gastroparesis.
• Diagnostic aid: Metoclopramide is used to facilitate gastrointestinal diagnostic procedures such as small bowel intubation and barium meal radiological examinations by accelerating gastric emptying and intestinal transit.
• Migraine-associated nausea and vomiting: The injectable formulation may be used to treat acute nausea and vomiting associated with migraine attacks, particularly when oral administration is not practical due to vomiting.

In pediatric patients aged 1 year and older, Metoclopramide Baxter injection is indicated as a second-line option for the prevention of delayed chemotherapy-induced nausea and vomiting and for the treatment of established postoperative nausea and vomiting.

What Should You Know Before Taking Metoclopramide Baxter?

Contraindications

Metoclopramide Baxter must not be used in certain clinical situations where its pharmacological effects could cause serious harm. Understanding these contraindications is essential for safe prescribing and administration. The following absolute contraindications apply:

• Hypersensitivity: Known hypersensitivity to metoclopramide or any of the excipients in the formulation. Previous allergic reactions to metoclopramide, including angioedema or anaphylaxis, are absolute contraindications.
• Gastrointestinal hemorrhage, mechanical obstruction, or perforation: The prokinetic effects of metoclopramide increase gastrointestinal motility and contractility, which could worsen bleeding, exacerbate obstruction, or cause perforation of compromised bowel wall.
• Pheochromocytoma (confirmed or suspected): Metoclopramide can cause hypertensive crisis in patients with pheochromocytoma by stimulating catecholamine release from the tumor. This combination is potentially life-threatening.
• History of tardive dyskinesia: Patients who have previously developed tardive dyskinesia from metoclopramide or other dopamine receptor antagonists must not receive metoclopramide again, as re-exposure carries a high risk of recurrence and potentially irreversible movement disorders.
• Epilepsy: Metoclopramide increases the frequency and intensity of seizures by lowering the seizure threshold, making it contraindicated in patients with epilepsy or a history of epileptic seizures.
• Parkinson’s disease: As a dopamine receptor antagonist, metoclopramide can worsen the symptoms of Parkinson’s disease by further reducing dopaminergic transmission in the basal ganglia.
• Concurrent use with levodopa or dopaminergic agonists: Metoclopramide and levodopa/dopamine agonists have mutually antagonistic effects. Metoclopramide blocks the dopamine receptors that levodopa acts upon, while levodopa counteracts the antiemetic effects of metoclopramide.
• Methemoglobinemia risk (with NADH cytochrome-b5 reductase deficiency): Metoclopramide can cause methemoglobinemia in patients with this enzyme deficiency, and its use is contraindicated in these patients.
• Infants under 1 year of age: Due to the significantly increased risk of extrapyramidal reactions in this age group.

Warnings and Precautions

Several important warnings apply to the use of metoclopramide that healthcare providers and patients should be aware of:

Extrapyramidal symptoms (EPS): Acute dystonic reactions (involuntary sustained muscle contractions), akathisia (motor restlessness), and parkinsonism can occur, particularly in children, young adults, and at higher doses. These reactions typically occur within 24–48 hours of treatment initiation and usually resolve within 24 hours of discontinuation. Acute dystonia can be treated with anticholinergic agents such as benztropine or diphenhydramine.

Neuroleptic malignant syndrome (NMS): Rarely, metoclopramide can cause NMS, a potentially fatal condition characterized by hyperthermia, muscle rigidity, altered consciousness, and autonomic instability. If NMS is suspected, metoclopramide must be discontinued immediately and aggressive supportive treatment initiated.

QT prolongation: Cases of QT prolongation and cardiac arrhythmias including torsade de pointes have been reported with metoclopramide, particularly with intravenous administration and in patients with pre-existing QT prolongation or those taking other QT-prolonging drugs. IV doses should be administered slowly over at least 3 minutes to minimize this risk.

Pregnancy and Breastfeeding

Metoclopramide can be used during pregnancy if clinically necessary. A large body of epidemiological data from multiple cohort studies involving over 50,000 exposed pregnancies has not demonstrated an increased risk of congenital malformations or fetotoxicity associated with metoclopramide use during the first trimester. Metoclopramide is in fact one of the most commonly used antiemetics for hyperemesis gravidarum (severe pregnancy-related nausea and vomiting) when other measures have failed. However, as with all medications during pregnancy, the expected benefits should outweigh the potential risks, and the lowest effective dose for the shortest possible duration should be used.

Metoclopramide is excreted into breast milk in small quantities. The estimated infant dose through breast milk is approximately 1–5.8% of the maternal weight-adjusted dose, which is generally considered clinically insignificant. Short-term use of metoclopramide during breastfeeding is generally compatible, although the theoretical possibility of adverse effects in the nursing infant (including extrapyramidal reactions) should be considered. Some older literature suggested that metoclopramide could be used as a galactogogue (to increase milk production) due to its prolactin-elevating effects, but this use is not recommended due to the risk of side effects and the availability of safer alternatives.

Fertility: Metoclopramide increases prolactin levels, which can cause galactorrhea, amenorrhea, gynecomastia, and impotence. These effects are reversible upon discontinuation. Elevated prolactin levels may impair fertility in both men and women, although this effect resolves when the drug is stopped.

How Does Metoclopramide Baxter Interact with Other Drugs?

Metoclopramide interacts with numerous medications through pharmacodynamic and pharmacokinetic mechanisms. Its effects on gastrointestinal motility can alter the rate and extent of absorption of co-administered oral drugs, while its dopamine-blocking and serotonergic properties can lead to additive or antagonistic effects with other centrally acting agents. Healthcare professionals should carefully review concomitant medications before initiating metoclopramide therapy.

Major Interactions

Minor Interactions

Due to metoclopramide's effect on accelerating gastric emptying, the rate and/or extent of absorption of many oral drugs can be altered. Drugs that are primarily absorbed in the stomach (such as digoxin) may have reduced absorption, while drugs absorbed in the small intestine (such as paracetamol and ciclosporin) may have faster and more complete absorption. Healthcare providers should consider these pharmacokinetic effects when prescribing oral medications concurrently with parenteral metoclopramide.

Metoclopramide is metabolized primarily by cytochrome P450 enzyme CYP2D6. Patients who are CYP2D6 poor metabolizers (approximately 7–10% of Caucasian populations) may have higher plasma concentrations of metoclopramide, potentially increasing the risk of adverse effects. Strong CYP2D6 inhibitors (such as fluoxetine, paroxetine, and quinidine) may also increase metoclopramide exposure, and dose reduction should be considered when these drugs are used concomitantly.

What Is the Correct Dosage of Metoclopramide Baxter?

Adults

Children (1 year and older)

Elderly

Renal and Hepatic Impairment

Renal impairment: In patients with end-stage renal disease (creatinine clearance ≤15 ml/min), the dose should be reduced by 75% (i.e., 25% of the normal dose). In moderate renal impairment (creatinine clearance 15–60 ml/min), reduce the dose by 50%. Metoclopramide is partially eliminated by renal excretion, and accumulation can occur in renal failure, increasing the risk of extrapyramidal reactions.

Hepatic impairment: In severe hepatic impairment (Child-Pugh C), the dose should be reduced by 50% due to reduced metabolic clearance. Monitor for increased adverse effects. In mild to moderate hepatic impairment, use with caution but standard doses may be appropriate with careful monitoring.

Missed Dose

As Metoclopramide Baxter injection is administered by healthcare professionals in clinical settings, missed doses are uncommon. If a scheduled dose is missed, it should be given as soon as possible, provided that sufficient time remains before the next scheduled dose (at least 6 hours between doses). The missed dose should be skipped entirely if the next dose is due within 6 hours. Doses should never be doubled to compensate for a missed administration.

Overdose

What Are the Side Effects of Metoclopramide Baxter?

Like all medicines, metoclopramide can cause side effects, although not everybody gets them. The following side effects have been reported during clinical trials and post-marketing surveillance. The frequencies are categorized according to internationally agreed conventions.

Extrapyramidal symptoms deserve special attention as they are among the most clinically significant adverse effects of metoclopramide. These movement disorders result from dopamine D2 receptor blockade in the basal ganglia and can manifest as several distinct syndromes. Acute dystonia involves sudden, involuntary sustained muscle contractions that can affect the neck (torticollis), jaw (trismus), tongue (protrusion), eyes (oculogyric crisis), or trunk (opisthotonus). These reactions are more common in young patients, particularly children and adolescents, and often occur within the first 24–48 hours of treatment. They can be promptly reversed with anticholinergic medications (benztropine or diphenhydramine) administered intravenously.

Akathisia is characterized by an intensely unpleasant sensation of inner restlessness and an inability to remain still, often accompanied by an irresistible urge to move the legs. This can be extremely distressing for patients and may be misdiagnosed as anxiety or agitation. Parkinsonism (drug-induced parkinsonism) presents with bradykinesia, rigidity, tremor, and shuffling gait, and is more common in elderly patients. Unlike acute dystonic reactions, parkinsonism typically develops more gradually over days to weeks of treatment.

Tardive dyskinesia is the most feared complication of metoclopramide therapy. Unlike acute extrapyramidal reactions, tardive dyskinesia develops after prolonged exposure (typically months to years, but occasionally after shorter periods) and is characterized by involuntary, repetitive movements primarily involving the orofacial muscles: lip smacking, tongue protrusion, jaw movements, grimacing, and chewing. Limb and trunk movements may also occur. The condition can be partially or completely irreversible, even after metoclopramide is discontinued. The EMA safety review in 2013 led to the recommendation to limit treatment duration to a maximum of 5 days specifically to minimize this risk.

How Should You Store Metoclopramide Baxter?

Proper storage of Metoclopramide Baxter injection is essential to maintain the stability, efficacy, and safety of the medication. As a sterile solution intended for parenteral administration, any compromise in storage conditions could affect the chemical stability of the active ingredient or the sterility of the product.

Temperature: Store at temperatures not exceeding 25°C (77°F). Do not freeze the solution. Freezing may alter the physicochemical properties of the formulation and could lead to precipitation or degradation of the active ingredient. If the solution has been accidentally frozen, it should be discarded and not used.

Light protection: Metoclopramide solution is sensitive to light, which can cause photodegradation of the active ingredient. Ampoules should be kept in the outer carton until immediately before use to protect from light exposure. Do not store ampoules outside of the carton for prolonged periods.

Single-use ampoules: Metoclopramide Baxter injection is supplied in single-use ampoules that do not contain antimicrobial preservatives. The product is intended for immediate use once opened. Any unused solution remaining in the ampoule after withdrawal of the required dose must be discarded immediately. Do not store opened ampoules for later use, as the sterility of the remaining solution cannot be guaranteed.

Visual inspection: Before use, the solution should be visually inspected for particulate matter, discoloration, or any signs of contamination. The solution should be clear and colorless. Do not use the product if the solution appears cloudy, discolored, or contains visible particles. Do not use if the ampoule appears damaged or the seal has been compromised.

Expiry date: Do not use Metoclopramide Baxter after the expiry date stated on the ampoule label and the outer carton. The expiry date refers to the last day of the stated month. Dispose of expired medications according to local pharmaceutical waste disposal regulations. Do not dispose of medications via household waste or wastewater.

Dilution and compatibility: When diluted for intravenous infusion, Metoclopramide Baxter injection is compatible with 0.9% sodium chloride solution and 5% glucose solution. Diluted solutions should be used immediately after preparation. Chemical and physical in-use stability has been demonstrated for up to 24 hours at 25°C for these dilutions, but from a microbiological standpoint, the product should be used immediately.

What Does Metoclopramide Baxter Contain?

Understanding the full composition of Metoclopramide Baxter injection is important for healthcare professionals, particularly when assessing compatibility with other intravenous medications, evaluating suitability for patients with known allergies or intolerances, and considering the sodium content for patients on sodium-restricted diets.

Active ingredient: Metoclopramide hydrochloride is the active pharmaceutical ingredient. Each 1 ml of solution contains 5 mg of metoclopramide hydrochloride monohydrate, equivalent to approximately 4.46 mg of metoclopramide free base. Metoclopramide hydrochloride is a white or almost white crystalline powder that is freely soluble in water. Its molecular formula is C₁₄H₂₂ClN₃O₂·HCl·H₂O, with a molecular weight of 354.3 g/mol (as the hydrochloride monohydrate).

Excipients:

• Sodium chloride: Used to adjust the tonicity of the solution to make it isotonic with blood and body fluids, reducing pain and tissue damage at the injection site. The sodium chloride content is adjusted so that the final solution has an osmolality compatible with intravenous and intramuscular administration.
• Hydrochloric acid and/or sodium hydroxide: Used for pH adjustment. The pH of the solution is adjusted to approximately 3.0–5.0 to ensure optimal stability of metoclopramide hydrochloride in solution and compatibility with parenteral administration.
• Water for injections: The solvent used to dissolve the active ingredient and excipients. It meets pharmacopoeial requirements for sterility, pyrogenicity, and particulate matter.

Packaging: Metoclopramide Baxter injection is supplied in clear glass ampoules (Type I hydrolytic glass) that provide chemical resistance and protect the solution from contamination. The ampoules are available in 2 ml (containing 10 mg metoclopramide hydrochloride) and 10 ml (containing 50 mg metoclopramide hydrochloride) sizes, packed in cardboard cartons. The ampoules are single-use only and do not contain preservatives.

Sodium content: Healthcare professionals should note that the solution contains sodium from sodium chloride and sodium hydroxide. The sodium content per dose should be considered for patients on controlled sodium diets, such as those with congestive heart failure, renal impairment, or hepatic cirrhosis with ascites.